FDA pom zoo ibrutinib rau kev kho mob ntawm tus kab mob graft-versus-host (cGVHD) rau cov menyuam yaus

Thaum Lub Yim Hli 24, 2022, Lub Chaw Saib Xyuas Khoom Noj thiab Tshuaj (FDA) tau pom zoo ibrutinib rau kev kho mob rau cov menyuam yaus hnub nyoog tshaj 1 xyoos uas muaj tus kab mob graft-versus-host (cGVHD) uas tau txais kev kho mob tom qab 1- lossis ntau kab. Qhov kev qhia pom zoo yog rau cov menyuam yaus, nrog rau qhov feem pua ​​​​​​ntawm kev teb tag nrho ntawm 60% ntawm lub lim tiam 25, thiab cov tshuaj suav nrog cov tshuaj ntsiav, cov ntsiav tshuaj thiab cov tshuaj haus.

Ibrutinib, ib qho BTK inhibitor uas tau tsim los ntawm Pharmacyclics/Johnson & Johnson, yog ib qho kinase inhibitor uas tau pom zoo ua ntej rau kev kho mob ntawm cov kab mob lymphocytic leukemia nrog rau cov kab mob cell lymphoma thiab lwm yam kab mob.

Suntech tsom mus rau kev tsim thiab tsim cov tshuaj intermediates thiab APIs siv cov thev naus laus zis ntsuab. Tam sim no, peb lub tuam txhab tau tsim peb yam khoom intermediates ntawm ibrutinib suav nrog C AS: 143900-44-1, C AS: 330792-70-6, C AS: 330786-24-8, tag nrho cov no tau raug muag hauv GMP factories ntau lawm. Ntawm lawv, cov intermediate ntawm C AS: 143900-44-1 yog tsim los ntawm cov thev naus laus zis tshuaj-enzymatic, uas muaj qhov zoo ntawm kev tiv thaiv ib puag ncig ntsuab, tus nqi qis thiab zoo. Txais tos rau kev sab laj thiab koom tes!